Altris AI, an artificial intelligence platform for optical coherence tomography (OCT) analysis that detects over 70 retina pathologies and biomarkers has been enhanced with additional quantification features for fluids and geographic atrophy (GA) tracking.
Developed in the United States by ophthalmologist Dr Maria Znamenska and Andrey Kuropyatnyk, the platform is now installed in more than 500 optometry centres and ophthalmic clinics globally.
…progression tracking informs GA management by visualising changes over time, supporting timely and accurate treatment decisions.
Fluid Quantification and Progression Tracking
The presence of fluids such as intraretinal cystoid fluid (IRC), diffuse oedema, subretinal fluid (SRF), and serous retinal pigment epithelium (RPE) detachment are critical biomarkers for conditions like neovascular age-related macular degeneration, diabetic macular oedema, diabetic retinopathy, and retinal vein occlusion. Accurate detection, quantification, and tracking of these fluids is essential for monitoring disease activity, evaluating treatment efficacy, and making informed prognoses.
Dr Znamenska and Mr Kuropyatnyk trained AI algorithms on millions of OCT scans, to provide precise and objective analysis of these fluid biomarkers.
Each of the four fluid types is localised and colour-coded for clarity. Quantitative metrics such as volume, area, and ETDRS grids (1, 3, and 6 mm) are calculated and presented in mm3 or nanolitres for comprehensive evaluation.
A progression tracking feature offers historical trend analysis with intuitive visualisations through graphs and percentages.
Additionally, fovea and central scan detection has been enhanced, especially in cases when the centre cannot be distinguished due to pathology presence or other reasons. The new model can find an accurate centre in 95% of cases; in other situations, it can efficiently estimate the centre location (as opposed to a simple analysis flow used by eye care professionals where the geometrical centre is selected). This advancement significantly enhances the precision of GA detection.
Further, progression tracking informs GA management by visualising changes over time, supporting timely and accurate treatment decisions.
All data on the Altris AI platform is encrypted and complies with European and United States regulations.
For further information, visit: Altris AI on YouTube.